angina perioperative management -act like a professor in anesthesia and explain this question to resident for md final exams

Reading File

Finding Sources

Reading File

Loading Image

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

I now have all the material needed to deliver a comprehensive, professor-quality teaching response. Let me compose it.

Perioperative Management of Angina - A Professor's Lecture for MD Final Exams

Settle in, residents. This is one of those topics that will come up in your final exam, your oral boards, and every single time you step into the OR with a patient who has coronary artery disease. Let me walk you through this the way a consultant anesthesiologist thinks - systematically, with the physiology always in front of us.

The Core Physiologic Framework - Never Forget This

Before anything else, stamp this into your brain: myocardial ischemia = supply/demand mismatch.

Oxygen supply depends on:

Coronary perfusion pressure (diastolic BP - LVEDP)
Diastolic filling time (heart rate - slower = more time)
Oxygen-carrying capacity (Hb, SaO2)
Coronary vascular tone (vasospasm vs. dilation)

Oxygen demand (MVO2) depends on:

Heart rate (most important - also reduces supply)
Wall stress (afterload x radius / 2 x wall thickness - LaPlace)
Contractility

The perioperative period is a physiologic storm - catecholamine surges, fluid shifts, pain, hypothermia, tachycardia, hypertension. Everything conspires to tip this balance toward ischemia. Your job is to prevent that.

Part 1: Preoperative Assessment

Step 1 - Urgency of Surgery (The Non-Negotiable First Step)

The ACC/AHA 2014 guideline begins here - and so must you.

Emergency surgery: Proceed immediately. Risk-stratify clinically, set up appropriate monitoring, and manage risk factors postoperatively. No time for workup.
Urgent/elective surgery: Proceed through the full stepwise algorithm below.

(Source: Morgan & Mikhail's Clinical Anesthesiology 7e; ACC/AHA 2014 guideline - Fleisher et al.)

Step 2 - Identify Active Cardiac Conditions (These STOP Elective Surgery)

These require cardiology evaluation and management BEFORE any elective procedure:

Condition	Example
Unstable coronary syndromes	Unstable angina, recent MI (<30 days)
Decompensated heart failure	NYHA Class IV, new or worsening HF
Significant arrhythmias	High-degree AV block, symptomatic SVT/VT
Severe valvular disease	Severe AS (AVA <1 cm²), severe symptomatic MR

Specifically for angina patients:

MI within 7 days = "active" condition - do NOT proceed
MI within 1 month with myocardium still at ischemic risk = also "active" - delay
Old MI with no ischemic territory at risk = low risk - proceed after full algorithm

(Morgan & Mikhail, p. 708)

Step 3 - Estimate Perioperative MACE Risk (Surgery-Specific + Clinical Risk)

Surgery-specific risk categories:

Risk Category	Expected MACE	Examples
Low	<1%	Superficial procedures, cataract, breast, endoscopic, ambulatory
Intermediate	1-5%	Carotid endarterectomy, intraperitoneal, intrathoracic, orthopedic, head & neck, prostate
High (Vascular)	>5%	Aortic repair, peripheral vascular revascularization

For low-risk surgery: Proceed regardless of clinical risk factors. No further cardiac testing needed. (Class III: No Benefit for further workup.)

(Washington Manual of Medical Therapeutics, p. 28-29)

The Revised Cardiac Risk Index (RCRI) - Lee's Index

For intermediate/high-risk surgery, quantify clinical risk using the RCRI. Score 1 point each for:

High-risk type of surgery
History of ischemic heart disease
History of congestive heart failure
History of cerebrovascular disease (TIA/stroke)
Insulin-dependent diabetes mellitus
Preoperative serum creatinine ≥2.0 mg/dL

RCRI Class	Points	Risk of MACE
I	0	~0.4%
II	1	~0.9%
III	2	~6.6%
IV	≥3	~11%

(Sabiston's Surgery, p. 3402; Barash's Clinical Anesthesia 9e)

RCRI risk stratification by surgical procedure type

Cardiac risk (MACE %) by RCRI class and surgical procedure - Barash's Clinical Anesthesia 9e

Step 4 - Functional Capacity (Metabolic Equivalents - METs)

Functional capacity is the most sensitive predictor of perioperative cardiac AND pulmonary complications.

1 MET = 3.5 mL O2/kg/min (basal metabolic rate of a 70-kg, 40-year-old man at rest)

METs	Activity	Clinical Significance
1 MET	Eating, dressing, desk work	Minimal - severe limitation
4 METs	Climbing 1-2 flights of stairs, walking briskly on flat ground	The critical threshold
7-8 METs	Heavy housework, golf, moderate swimming	Good capacity
>10 METs	Strenuous sports (tennis, basketball, squash)	Excellent capacity

The rule: patients who cannot achieve ≥4 METs have increased perioperative cardiac events and long-term risk.

(Sabiston's Surgery, p. 2791-2804; Washington Manual, p. 550)

The Full ACC/AHA Decision Algorithm

ACC/AHA stepwise approach to perioperative cardiac assessment for CAD

Stepwise perioperative cardiac assessment for CAD - Morgan & Mikhail's Clinical Anesthesiology 7e (ACC/AHA 2014)

Exam-ready summary of the algorithm:

Emergency? → Proceed, manage clinically
ACS present? → Cardiology referral, GDMT (STEMI/NSTEMI CPGs)
Estimate MACE risk (RCRI + surgical risk)
- Low risk (<1%) → No further testing, proceed
- Elevated risk → Go to functional capacity assessment
Functional capacity ≥4 METs?
- Moderate/good (4-10 METs) → Proceed (Class IIb: no further testing)
- Excellent (>10 METs) → Proceed (Class IIa)
- Poor or unknown (<4 METs) → Question 5
Will further testing change management?
- Yes → Pharmacologic stress testing (Class IIa). If abnormal → coronary revascularization per existing CPGs
- No → Proceed per GDMT or consider alternate/palliative strategy

Preoperative Testing - When to Order What

ECG:

Indicated for patients with known CAD, significant arrhythmia, peripheral artery disease, cerebrovascular disease prior to intermediate/high-risk surgery (Class IIa)
May be considered in asymptomatic patients before intermediate/high-risk surgery (Class IIb)
NOT useful in asymptomatic patients before low-risk surgery (Class III)

Resting Echocardiography:

If dyspnea of unknown origin
Known LV dysfunction - if no echo within 1 year or significant functional change

Stress Testing (Exercise or Pharmacologic Dobutamine/Adenosine):

Reserve for elevated RCRI risk + poor/unknown functional capacity (<4 METs) + testing will change management
Pharmacologic stress (dobutamine stress echo, nuclear perfusion imaging) when patient cannot exercise
NOT recommended for low-risk surgery or good functional capacity (>4 METs)

(Sabiston's Surgery, p. 3427-3430; Washington Manual, p. 570-574)

Part 2: Preoperative Medical Optimization

Beta-Blockers - The Most Exam-Relevant Drug

This is nuanced - know the POISE trial.

POISE trial (Devereaux et al.): Perioperative metoprolol (high-dose, not titrated, started day-of-surgery) reduced perioperative MI but increased overall mortality and significantly increased stroke risk.

Current ACC/AHA recommendations:

Continue beta-blockers in patients already receiving chronic therapy - do NOT withdraw (evidence A)
Never start beta-blockers de novo on the day of surgery
Consider initiating beta-blockade perioperatively (titrated, well in advance) in very select patients: intermediate/high-risk ischemia on stress testing, OR ≥3 RCRI risk factors

The key teaching point: beta blockade paradoxically increases stroke risk while reducing MI risk. A patient with concomitant cerebrovascular disease needs careful weighing before initiating new beta-blocker therapy.

(Harrison's Internal Medicine 22e, p. 3951; Miller's Anesthesia 10e)

Statins

Continue existing statin therapy perioperatively (evidence B) - important for plaque stabilization, anti-inflammatory effects
Initiate statin therapy for patients undergoing vascular surgery (evidence B)
Multiple trials show reduced perioperative MACE and mortality, especially in vascular surgery
The LOAD trial showed no benefit from atorvastatin loading in statin-naive patients for non-vascular surgery - so be selective

(Harrison's 22e, p. 3951; Washington Manual, p. 596-602)

ACE Inhibitors / ARBs

Continue for heart failure or hypertension management (maintain RAAS continuity)
Hold on the morning of surgery if used solely for hypertension - reduces risk of severe intraoperative hypotension
Resume postoperatively when hemodynamically stable

Aspirin / Antiplatelet Therapy

In the ABSENCE of coronary stents:

Continuing aspirin does NOT prevent cardiovascular complications perioperatively
BUT does increase major bleeding risk (which is itself a risk factor for perioperative stroke)
General recommendation: hold aspirin 72 hours before surgery for most patients
Exception: consider continuing in patients with high-risk atherosclerotic CVD or recent stroke within 9 months

Post-PCI / Coronary Stent Patients:

Most dangerous period: 4-6 weeks post-stent implantation (highest stent thrombosis risk)
DAPT (Dual Antiplatelet Therapy) duration:
- BMS (bare metal stent): minimum 30 days DAPT before elective surgery
- DES (drug-eluting stent) for stable disease: minimum 6 months DAPT
- DES post-ACS: minimum 12 months DAPT
Drug washout before surgery: clopidogrel - 5 days; prasugrel - 7 days; ticagrelor - 3-5 days
If surgery truly cannot be delayed: continue aspirin, discuss with cardiology

(Harrison's 22e; Sabiston's Surgery, p. 3456-3462; Miller's Anesthesia 10e)

Prophylactic Revascularization - A Common Misconception

Do NOT revascularize prophylactically just to reduce perioperative risk.

The CARP Trial (Coronary Artery Revascularization Prophylaxis): Patients with proven significant CAD scheduled for vascular surgery randomized to revascularization vs. no revascularization - NO difference in 30-day MI, death, or long-term mortality.

Revascularize only when indicated by guidelines on their own merits (e.g., left main disease, three-vessel disease with LV dysfunction, refractory angina despite GDMT).

(Washington Manual, p. 610-614)

Part 3: Intraoperative Management

Monitoring

Standard ASA monitoring (ECG, pulse oximetry, NIBP, capnography, temperature) is the minimum for all.

For patients with angina or significant CAD:

5-lead ECG with ST-segment monitoring: leads II (inferior territory), V4 or V5 (anterior/lateral territory - most sensitive for LAD ischemia). Combination of II + V5 detects ~80% of ischemic events
Arterial line for continuous BP monitoring in moderate/high-risk cases
Central venous access as indicated
TEE (transesophageal echocardiography): The most sensitive intraoperative monitor for ischemia - detects new regional wall motion abnormalities (RWMA) before ECG changes or hemodynamic compromise. Gold standard for high-risk cases. (Miller's Anesthesia 10e, p. 3457)
Pulmonary artery catheter: selected cases with severe LV dysfunction or anticipated major fluid shifts

Anesthetic Goals - The Hemodynamic Targets

Your anesthetic plan must maintain the supply/demand balance. Think HR x BP:

Goal	Rationale
Heart rate: 60-80 bpm (or near baseline)	Reduces MVO2; prolongs diastole → improves coronary perfusion
Avoid tachycardia	Most dangerous determinant of ischemia - increases demand + decreases supply
Maintain diastolic BP	Coronary perfusion pressure depends on diastole
Avoid hypotension	MAP <65 mmHg = inadequate coronary perfusion
Avoid hypertension	Increased afterload = increased wall stress = increased MVO2
Maintain normothermia	Hypothermia → shivering → catecholamine surge → tachycardia

Choice of Anesthetic Technique

General vs. Regional: No technique has been definitively shown superior for cardiac outcomes. The principle is maintaining hemodynamic stability with either.

Volatile agents (sevoflurane, desflurane, isoflurane): Evidence of ischemic preconditioning - activate KATP channels, mimic the cellular protection of brief ischemia. This is now well-established. Sevoflurane preferred for cardiac cases due to less sympathomimetic effect.

Opioids: High-dose opioid techniques historically used for cardiac surgery to blunt stress response. Fentanyl, sufentanil, remifentanil all used.

Avoid: desflurane in ischemic patients (can cause reflex tachycardia from sympathetic activation); ketamine in high doses (tachycardia, hypertension).

Intraoperative Ischemia - Recognition and Treatment

ECG signs:

ST depression >1 mm in two contiguous leads (subendocardial ischemia - most common pattern)
ST elevation (transmural ischemia - more alarming)
New T-wave inversions
New LBBB

TEE signs: New regional wall motion abnormality (RWMA) - may precede ECG changes by minutes

Treatment - depends on the mechanism (supply vs. demand):

Clinical Manifestation	Intervention
↑ Heart rate (increased demand)	Beta-blocker IV, ↑ anesthetic depth
↑ Blood pressure (increased demand)	↑ anesthetic depth, nitroglycerin, labetalol
↑ PCWP (increased demand)	Nitroglycerin
↓ Heart rate (decreased supply)	Atropine, pacing
↓ Blood pressure (decreased supply)	↓ anesthetic depth, vasoconstrictors (phenylephrine/norepinephrine)
↑ PCWP with low supply	Nitroglycerin + inotrope
No hemodynamic changes	Nitroglycerin, calcium channel blockers, consider heparin

(Barash's Clinical Anesthesia 9e - Table 39-2, p. 3290)

Nitroglycerin (the workhorse):

Drug of choice for acute intraoperative ischemia
Works via systemic venodilation (↓ preload, ↓ LVEDP) + coronary arterial dilation including collateral beds
Effective at stenosed coronaries
Caution: Higher doses cause systemic hypotension → reflex tachycardia → worsens ischemia
Prophylactic nitroglycerin infusion does NOT prevent intraoperative ischemia or reduce cardiac complications
Side effect at high/prolonged doses: methemoglobinemia

(Barash's Clinical Anesthesia 9e, p. 2640)

Part 4: Postoperative Management

High-Risk Period

Most perioperative MIs occur within 48-72 hours of surgery, with the majority in the first 24 hours. Most are clinically silent - no chest pain (due to residual analgesia, sedation, diabetic neuropathy).

Mechanisms:

Plaque rupture + thrombosis (most common - similar to spontaneous ACS)
Demand ischemia from tachycardia, hypotension, pain, anemia, hypoxia

Postoperative Monitoring

Per ACC/AHA 2014 guidelines:

Routine ECGs and troponins are NOT recommended in all patients
In high cardiac risk patients: the benefit of routine troponin/ECG surveillance remains uncertain
Any symptomatic event (chest pain, new hemodynamic instability, new arrhythmia, hypoxia): obtain ECG and troponin immediately and treat as ACS

MINS (Myocardial Injury after Non-cardiac Surgery): Asymptomatic troponin elevation after surgery is now recognized as an entity with significantly increased 30-day mortality risk. Management remains controversial and evolving.

Postoperative Treatment

For confirmed postoperative MI:

Treat as standard ACS protocol
Key caveat: Bleeding risk from anticoagulants must be carefully weighed against thrombotic risk given recent surgery
Dual antiplatelet therapy decisions require surgical team input regarding bleeding risk
Urgent cardiology consultation
Consider coronary angiography/PCI timing based on clinical stability and surgical bleeding risk

Continue Chronic Medications

Resume beta-blockers, statins, ACE inhibitors/ARBs postoperatively as soon as patient is hemodynamically stable and tolerating oral medications
Abrupt beta-blocker withdrawal perioperatively is associated with rebound tachycardia, hypertension, and ischemia

Summary Table for Exam Revision

Phase	Key Actions
Preoperative	Urgency? → Active conditions? → MACE risk (RCRI + surgery) → METs → Further testing if needed
Medications	Continue: beta-blockers, statins. Hold morning-of or titrate: ACE-i/ARB. Antiplatelet: per stent type/indication
Stent patients	BMS: delay ≥30 days. DES: delay ≥6 months (stable) or 12 months (post-ACS)
Intraoperative	5-lead ECG (II+V5), arterial line, consider TEE. Target HR 60-80, maintain MAP, avoid tachycardia
Ischemia Rx	Treat by mechanism: demand (beta-blocker, ↑ depth) vs. supply (vasopressor, ↓ depth, pacing) + nitroglycerin
Postoperative	Peak risk 0-72h. Silent MIs common. Routine troponin not mandatory. Treat symptoms as ACS. Resume meds early.

Exam Hot Tips

The single most important intraoperative monitor for ischemia = TEE (wall motion abnormalities precede ECG changes)
Tachycardia is the most dangerous hemodynamic derangement in ischemic heart disease - it both increases demand AND decreases supply
POISE trial lesson = high-dose perioperative beta-blocker initiation reduces MI but increases stroke and death; always titrate slowly in advance
Prophylactic revascularization before noncardiac surgery is NOT indicated (CARP trial)
<4 METs = poor functional capacity = increased perioperative cardiac risk
Nitroglycerin prophylaxis infusion = does NOT prevent intraoperative ischemia
DES stent = minimum 6 months (stable) or 12 months (post-ACS) before elective surgery to complete DAPT
Most perioperative MIs are silent - don't wait for chest pain postoperatively in a sedated patient

"In anesthesia, prevention is everything. You protect the heart not with a single drug, but with a strategy - optimized before the patient enters the OR, maintained precisely during surgery, and continued vigilantly after. Every drug, every monitor, every hemodynamic target is there to preserve the supply/demand balance. That is the discipline of perioperative cardiac management."

References: Morgan & Mikhail's Clinical Anesthesiology 7e (pp. 708-713); Barash's Clinical Anesthesia 9e (pp. 3290-3291, Table 39-2); Harrison's Principles of Internal Medicine 22e (pp. 3950-3951); Sabiston's Textbook of Surgery (pp. 3402-3460); Washington Manual of Medical Therapeutics (pp. 528-630); Miller's Anesthesia 10e (pp. 3993-3994); ACC/AHA 2014 Perioperative Cardiovascular Evaluation Guideline (Fleisher et al., J Am Coll Cardiol 2014).

cardiac arrest in ot - causes with recent guidelines - act like professor in anesthesia and explain it to resident with viva questions

Reading File

Finding Sources

Searching PubMed

"cardiac arrest" AND "operating room" AND "perioperative"

Reading File

Reading Article

PMID: 37218626

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Loading Image

Finding Sources

Reading File

Finding Sources

I now have all the comprehensive content I need. Let me compose the full professor-level teaching lecture.

Cardiac Arrest in the Operating Theatre - A Professor's Teaching Lecture for MD Final Viva

"Residents, pay close attention. Cardiac arrest in the OT is the ultimate test of the anesthesiologist. You are surrounded by every possible resource - monitoring, drugs, equipment, team. Yet the mortality remains above 50% in many series. Why? Because panic replaces protocol. Today, we remove the panic. By the end of this session, you will have a systematic, physiologically grounded response to this emergency."

Section 1: Epidemiology and Why the OT is Unique

Let's start with some numbers that should both reassure and humble you.

Cardiac arrest occurs in approximately 1 in every 10,000 anesthetics when the cause is anesthesia-related
Data from the ACS NSQIP database shows a broader incidence - 1 in every 203 surgical patients - with over 70% dying within one month
When cardiac arrest is purely anesthesia-related, successful resuscitation occurs approximately 90% of the time
Overall in-hospital survival to discharge is ~25% for perioperative cardiac arrest

Why is the OT the best place for cardiac arrest?

Three reasons:

The patient is already fully monitored - you see it the moment it happens
There is immediate expert personnel present
All resuscitation equipment is at hand - defibrillator, drugs, airway

The causes are different from community cardiac arrest. In the OT, the cause is usually known or knowable within 60 seconds. This changes everything about your approach.

(Barash's Clinical Anesthesia 9e; 2023 ESAIC/ESTES Consensus Guideline - Hinkelbein et al., Eur J Anaesthesiol 2023)

Section 2: Classification of Causes - The "ANESTHESIA + H's & T's" Framework

I want you to think in two parallel streams:

Anesthesia/surgery-specific causes (unique to OT)
General ACLS causes (H's and T's - same as anywhere else)

Stream A: OT-Specific Causes (The Examiner's Favorites)

1. Airway Catastrophe - Hypoxia from Failed Intubation / Oesophageal Intubation

The #1 anesthesia-related cause of cardiac arrest. Unrecognized oesophageal intubation, failed airway in a can't intubate-can't oxygenate (CICO) situation, or airway obstruction.

Mechanism: Hypoxia → bradycardia → asystole. This follows a predictable downward spiral.

Prevention/Recognition: Capnography is MANDATORY. An absent or falling ETCO2 waveform after intubation = oesophageal intubation until proven otherwise. Never rely on chest rise, breath sounds, or stomach sounds alone.

Management: Immediately revert to basic airway - bag-mask ventilation, supraglottic airway (LMA). If all fail → emergency front-of-neck access (eFONA) - surgical cricothyroidotomy.

2. Drug-Related Causes

(a) Anaphylaxis Severe IgE-mediated (or direct mast cell) reaction leading to massive vasodilation, bronchospasm, and cardiovascular collapse.

Common triggers in OT: Neuromuscular blocking agents (most common - rocuronium, succinylcholine), latex, antibiotics, chlorhexidine, contrast media, colloids.

Recognition: Cardiovascular collapse (hypotension, tachycardia) + bronchospasm + urticaria. But in the anesthetized patient, skin signs may be absent or masked by drapes.

Treatment:

Epinephrine IV is the first-line drug - 0.1-0.5 mg (1:10,000) IV boluses, escalating as needed. NOT just IM.
Stop the trigger
Aggressive IV fluids (1-2 L rapid)
Bronchodilators (salbutamol nebulized or IV)
Antihistamines and corticosteroids are secondary

(b) Succinylcholine-Induced Hyperkalemia In patients with burns, spinal cord injury, prolonged immobilization, rhabdomyolysis, or critical illness - upregulation of extra-junctional acetylcholine receptors causes massive K+ efflux.

Time course: Minimum 4 days post-injury before dangerous response occurs. Can be catastrophic months later.

Treatment: Stop succinylcholine. Calcium gluconate (membrane stabilization), insulin + dextrose, sodium bicarbonate.

(c) Local Anesthetic Systemic Toxicity (LAST) Accidental intravascular injection or rapid absorption of local anesthetic causing CNS excitation followed by cardiovascular collapse.

Signs: Metallic taste, tinnitus, perioral numbness → seizures → cardiovascular collapse → cardiac arrest. Bupivacaine causes particularly refractory VF due to Na+ channel blockade.

Prevention: Test dose with epinephrine marker (1:200,000), incremental injection (3-5 mL every 90-120 seconds), aspirate before each injection.

Treatment - LAST Protocol (ASRA Guidelines):

Stop injection immediately
Airway management, 100% O2, IV access
Seizures: benzodiazepine (NOT propofol - cardiovascular depression)
20% Lipid Emulsion (Intralipid) - the specific antidote:
- Bolus: 1.5 mL/kg over 1 minute
- Infusion: 0.25 mL/kg/min
- Repeat bolus every 3-5 min if no response
- Maximum total dose: 10 mL/kg over first 30 minutes
For cardiac arrest: standard ACLS + lipid emulsion
Avoid propofol as lipid emulsion substitute (insufficient lipid load, adds cardiac depression)

(Miller's Anesthesia 10e, p. 1973; Barash's 9e, p. 2866)

3. Total Spinal / High Spinal Anesthesia

Excessive rostral spread of intrathecal local anesthetic, or accidental subarachnoid injection during epidural placement.

Mechanism: T1-T4 blockade → cardiac sympathetic denervation → bradycardia/asystole. Phrenic nerve (C3-5) blockade → respiratory arrest. Higher spread → brainstem → loss of consciousness.

Classic progression:

Hand/arm tingling (cervical root involvement)
Intercostal paralysis
Diaphragm paralysis (C3-5)
Apnea + LOC (brainstem)
Cardiac arrest

Treatment: Supportive. Immediate:

100% O2, secure airway (intubate)
Vasopressors (epinephrine/phenylephrine IV) for hypotension
Atropine/epinephrine for bradycardia
Psychological support and reassurance (patient may be conscious initially)
Block resolves with time - generally recovers fully

(Miller's Anesthesia 10e, p. 6127)

4. Malignant Hyperthermia (MH)

Pharmacogenetic disorder (RYR1 gene mutation) causing uncontrolled Ca2+ release from sarcoplasmic reticulum after triggering agents.

Triggers: Volatile anesthetic agents (halothane, sevoflurane, desflurane, isoflurane) + succinylcholine.

Signs (early): Masseter spasm after succinylcholine, unexplained tachycardia, rising ETCO2 (despite adequate ventilation), hyperthermia (late sign), metabolic acidosis, hyperkalemia.

ETCO2 rise is often the FIRST sign.

Treatment (MH Crisis Protocol):

Stop trigger agents immediately
Call for help + MH hotline
Dantrolene 2.5 mg/kg IV rapidly, repeat until ETCO2 falls (continue until crisis resolves, up to 10 mg/kg or more)
100% O2 at high flows to wash out volatile agents
Active cooling (cold IV fluids, ice packs, cooled lavage)
Treat hyperkalemia aggressively (cardiac arrest from K+ is a major risk)
Bicarbonate for severe acidosis
Continue surgery only if life-threatening

5. Venous Air Embolism (VAE)

Air entrainment into venous circulation causing an air-lock in the right heart/pulmonary circulation.

High-risk situations: Sitting craniotomy, neurosurgery with head elevated, total hip replacement (especially with pneumatic tourniquet deflation), laparoscopy (CO2 embolism), central line insertion.

Signs: Sudden unexplained hypotension, desaturation, "mill-wheel" murmur (churning sound in heart), sudden decrease in ETCO2 (air reduces pulmonary perfusion).

Treatment:

Flood surgical field / stop air entry
Aspirate via right heart/CVP catheter
Place patient left lateral decubitus + Trendelenburg (Durant maneuver) - moves air bubble away from right ventricular outflow tract
100% O2 to dissolve air (NO nitrous oxide - it expands air bubble)
CPR if arrest occurs - chest compressions may fragment large bolus

6. Tension Pneumothorax

Particularly relevant during positive-pressure ventilation, central line insertion, or thoracic/laparoscopic procedures.

Mechanism: Air accumulation in pleural space with mediastinal shift → obstructive shock → cardiac arrest. Positive pressure ventilation dramatically worsens tension.

Signs: Unilateral absent breath sounds, sudden hypotension, tracheal deviation (late), elevated airway pressures, desaturation, cardiovascular collapse.

Treatment: Do NOT wait for CXR in arrest. Immediate needle decompression (2nd intercostal space, mid-clavicular line) as emergency temporizing measure → definitive intercostal tube thoracostomy.

7. Cardiac Tamponade

Can occur post-cardiac surgery (acute pericardial hemorrhage), central line placement (cardiac perforation), or in trauma cases.

Beck's Triad: Hypotension + raised JVP + muffled heart sounds. But in anesthetized patient, Beck's triad may be incomplete.

Signs in OT: Unexplained hypotension, equalization of filling pressures (CVP = PAWP), decreasing cardiac output, paradoxical pulse, tachycardia, pulsus paradoxus.

Treatment: Pericardiocentesis (subxiphoid approach) - Seldinger technique. Definitive: surgical drainage. TEE is invaluable for diagnosis.

8. Acute Coronary Syndrome / Massive MI

Plaque rupture triggered by surgical stress, tachycardia, hypotension, anemia, or hypercoagulable state.

Treatment: Standard ACLS. Post-ROSC: urgent 12-lead ECG, cardiology consultation, cath lab if STEMI.

Stream B: The H's and T's (AHA 2020 ACLS Guidelines)

These apply in OT just as in any other setting:

H's	T's
Hypovolemia - massive hemorrhage	Tension pneumothorax
Hypoxia - airway failure, aspiration	Tamponade (cardiac)
Hydrogen ion (Acidosis)	Toxins - drugs, local anesthetics
Hypo/Hyperkalemia	Thrombosis, pulmonary (massive PE)
Hypothermia - cold irrigation, prolonged surgery	Thrombosis, coronary (MI)
Hypoglycemia

(Barash's Clinical Anesthesia 9e, p. 2243; AHA 2020 ACLS Guidelines)

Section 3: Recognition in the OT

In a monitored patient, recognition should be immediate. Do not spend >10 seconds confirming - if the patient is pulseless and unresponsive, start CPR.

Key monitors to watch:

SpO2 waveform loss (first sign often)
ETCO2 sudden drop to zero (no cardiac output = no CO2 delivery to lungs)
Arterial line trace goes flat
ECG: VF, pulseless VT, asystole, PEA
Surgical field: sudden "empty" vessels, no bleeding

ETCO2 is your CPR quality monitor:

During good CPR, ETCO2 should be >10 mmHg
ETCO2 >40 mmHg during CPR = very likely ROSC
Helps guide compression quality without interrupting CPR

Section 4: The OT Cardiac Arrest Algorithm - 2020 AHA / 2023 ESAIC-ESTES

Immediate Response (First 30 seconds)

Call for help - designate team leader immediately
Confirm cardiac arrest - pulse check <10 seconds
Start high-quality CPR - 30:2 if not intubated; continuous compressions if intubated
Apply defibrillator pads
Assess rhythm

CPR Quality Standards (2020 AHA)

Parameter	Target
Rate	100-120 compressions/min
Depth	5-6 cm sternum depression
Recoil	Full chest recoil (no leaning)
Interruptions	Minimize - <10 sec pause
Ventilation (intubated)	1 breath every 6 seconds (10/min)
Ventilation rate	DO NOT over-ventilate - increases intrathoracic pressure, reduces venous return

Shockable vs. Non-Shockable Rhythms

Shockable: VF / Pulseless VT

Shock immediately: Biphasic 120-200J, monophasic 360J
Resume CPR immediately after shock (do NOT check pulse first)
Epinephrine 1 mg IV every 3-5 minutes (after 2nd shock)
Amiodarone 300 mg IV bolus (after 3rd shock) - for refractory VF/VT
Internal defibrillation (open chest): 10-50J if chest is open

Non-Shockable: Asystole / PEA

CPR immediately
Epinephrine 1 mg IV as soon as possible, then every 3-5 minutes
Identify and treat H's and T's
Atropine: NOT recommended for asystole/PEA (insufficient evidence, not harmful but not helpful)

Epinephrine mechanism in arrest:

All benefit comes from alpha-adrenergic vasoconstriction
Increases aortic diastolic pressure → increases coronary perfusion pressure → improves myocardial blood flow
Beta effects are actually detrimental (increase post-ROSC arrhythmias and O2 demand)

(Barash's Clinical Anesthesia 9e, p. 1928-1932)

Section 5: OT-Specific Modifications to Standard ACLS

The 2023 ESAIC/ESTES Consensus Guideline (Hinkelbein et al.) emphasizes several OT-specific points:

Airway advantage: The anesthesiologist can maintain a definitive airway immediately - use it. Continuous capnography during CPR is essential.
Open Chest Cardiac Massage (OCCM): In cardiac surgery cases or when chest is already open - internal cardiac massage is far more efficient than external compressions (generates higher cardiac output). Use internal paddles for defibrillation starting at 10J.
Position: External CPR in prone-positioned patients - place pads at T7 and right shoulder; compressions at same location as standard. Do NOT routinely reposition prone patients unless compressions are completely ineffective.
Drug delivery: Intraosseous (IO) access - humeral IO is rapid and allows 100 mL/min flow. If no IV access, use IO. Do NOT use endotracheal route as primary route.
TEE: Provides real-time diagnosis of cause (wall motion abnormality, pericardial effusion, RV failure, PE) without interrupting compressions. Gold standard for intraoperative diagnosis.
Surgical control of hemorrhage: If cardiac arrest is due to surgical hemorrhage, surgical hemostasis takes priority alongside CPR.
REBOA (Resuscitative Endovascular Balloon Occlusion of the Aorta): In select trauma cases, can temporize hemorrhagic cardiac arrest by occluding descending aorta - complex, requires specific training and infrastructure.

Section 6: Drugs in OT Cardiac Arrest - Quick Reference

Drug	Dose	Indication
Epinephrine	1 mg IV every 3-5 min	VF, PEA, Asystole - ALL rhythms
Amiodarone	300 mg IV bolus, then 150 mg	Refractory VF/VT (after 3rd shock)
Lidocaine	1-1.5 mg/kg IV	Alternate to amiodarone if not available
Atropine	NOT recommended in arrest	No benefit in asystole/PEA
Calcium gluconate	10-20 mL of 10% IV	Hyperkalemia, hypocalcemia, Ca-channel blocker OD
Sodium bicarbonate	1 mEq/kg IV	Hyperkalemia, tricyclic antidepressant OD, severe acidosis >10 min arrest
Dantrolene	2.5 mg/kg IV bolus	Malignant hyperthermia
20% Lipid emulsion	1.5 mL/kg bolus then 0.25 mL/kg/min	LAST (local anesthetic toxicity)
Magnesium sulfate	1-2 g IV	Torsades de pointes, hypomagnesemia
Vasopressin	40 units IV (single dose)	Can replace 1st or 2nd dose of epinephrine

Section 7: Post-Resuscitation Care (Post-ROSC)

The battle doesn't end with ROSC. "Post-resuscitation disease" is real.

Post-Cardiac Arrest Care Algorithm - AHA 2020 (Barash's Clinical Anesthesia 9e)

Initial Stabilization Phase:

Airway:

Secure airway with ETT + confirm with waveform capnography
Ventilate at 10 breaths/min (start)

Respiratory:

Titrate FiO2: SpO2 92-98% (avoid hyperoxia - generates free radicals)
Titrate ventilation: PaCO2 35-45 mmHg (avoid hypocapnia - causes cerebral vasoconstriction)

Hemodynamic:

Systolic BP >90 mmHg, MAP >65 mmHg
Vasopressors/inotropes as needed

Continued Management:

12-lead ECG immediately - if STEMI → urgent cath lab. Do not let a recent surgery deter you if STEMI is confirmed and the culprit vessel is likely the cause of arrest.

Targeted Temperature Management (TTM):

If patient is comatose (not following commands) after ROSC → TTM at 32-36°C for 24 hours
Prevents secondary neurological injury from reperfusion
Use cooling device with feedback loop
Monitor core temperature continuously (esophageal, rectal, bladder)
TTM + EEG monitoring + brain CT are all part of the comatose post-arrest bundle

Other:

Maintain normoglycemia (hyperglycemia worsens neurological outcome)
Continuous or intermittent EEG (detect subclinical seizures)
Lung-protective ventilation
Avoid hyperthermia after TTM completion

(Barash's Clinical Anesthesia 9e, p. 2301-2344; AHA 2020)

Section 8: DNAR Orders in the OT

This is a medicolegal topic that will definitely appear in your viva.

Key facts:

Up to 60% of anesthesiologists mistakenly believe DNAR orders are automatically suspended in the OT
This is legally and ethically wrong - advance directives are binding
ASA, American College of Surgeons, AORN, and The Joint Commission all require reconsideration, not abandonment, of DNAR in the perioperative period
The discussion must occur preoperatively, must be documented, and must be shared with the full OT team
Families have successfully sued for damages when DNAR instructions were ignored

(Miller's Anesthesia 10e, p. 634)

Section 9: Prevention - The Anesthesiologist's Priority

"It is far better to prevent a cardiac arrest than to manage one."

Prevention Strategy	Target
Capnography monitoring	Detect oesophageal intubation, monitor CPR quality
Difficult airway algorithm preparation	Avoid CICO situation
Test dose in regional anesthesia	Detect intravascular injection (LAST)
Incremental local anesthetic injection	Limit LAST risk
Avoid succinylcholine in at-risk patients	Prevent hyperkalemic arrest
MH triggering agent avoidance (susceptible patients)	Prevent MH crisis
Dantrolene stocked within OR	MH emergency readiness
Regular simulation and drill practice	Team performance in crisis
Crew Resource Management (CRM)	Communication errors reduced
Cognitive aids / checklists	Stanford Emergency Manuals in every OT

VIVA QUESTIONS - Rapid Fire

Professor to Resident - typical MD Final Viva format

Q1. What is the incidence of cardiac arrest in the OT?

Approximately 1 in 10,000 anesthetics when purely anesthesia-related; 1 in 203 surgical patients in the broader NSQIP database.

Q2. Why does the OT have the highest CPR success rate within the hospital?

Because patients are already fully monitored, arrest is recognized immediately, expert personnel are present, and all resuscitation equipment is immediately available. When anesthesia-related, ROSC approaches 90%.

Q3. Name the H's and T's for reversible causes of cardiac arrest.

H's: Hypovolemia, Hypoxia, Hydrogen ion (acidosis), Hypo/Hyperkalemia, Hypothermia, Hypoglycemia. T's: Tension pneumothorax, Tamponade, Toxins, Thrombosis-pulmonary, Thrombosis-coronary.

Q4. What is the drug of choice for cardiac arrest? What is its mechanism?

Epinephrine 1 mg IV every 3-5 minutes. Its benefit is entirely through alpha-adrenergic vasoconstriction - increases aortic diastolic pressure → raises coronary perfusion pressure → improves myocardial blood flow. Beta effects are not beneficial during arrest.

Q5. A patient develops sudden hypotension, absent breath sounds on one side, and rising airway pressures during mechanical ventilation. What do you do?

Tension pneumothorax. Stop ventilation briefly to confirm, immediately perform needle decompression at 2nd intercostal space, midclavicular line, followed by intercostal tube thoracostomy. Do NOT wait for CXR in haemodynamic compromise.

Q6. You give succinylcholine to a patient who was in an ICU for 3 weeks with Guillain-Barré syndrome. She arrests 2 minutes later. What happened? How do you treat it?

Succinylcholine-induced hyperkalemia. Upregulation of extrajunctional acetylcholine receptors causes massive K+ efflux. Treatment: standard CPR, calcium gluconate 10 mL IV (membrane stabilization), insulin + dextrose, sodium bicarbonate. Avoid succinylcholine in any patient with >4 days of denervation, burns, prolonged immobilization, or critical illness.

Q7. A patient undergoing a femoral nerve block arrests. The preceding signs were tinnitus, then generalized convulsion. What is the diagnosis and treatment?

LAST - Local Anesthetic Systemic Toxicity. Specific treatment is 20% lipid emulsion: 1.5 mL/kg bolus over 1 minute → infusion at 0.25 mL/kg/min. Repeat bolus every 3-5 min. Maximum 10 mL/kg over 30 min. Standard ACLS simultaneously. Avoid propofol as a substitute - it adds cardiovascular depression and the lipid concentration is insufficient.

Q8. What are the signs of malignant hyperthermia and what is the specific drug?

Unexplained tachycardia + rising ETCO2 (most important early sign) + masseter spasm (after succinylcholine) + metabolic acidosis + hyperkalemia + hyperthermia (late). Specific treatment: Dantrolene 2.5 mg/kg IV bolus (repeat until ETCO2 falls), plus stop triggers, active cooling, treat hyperkalemia. Dantrolene prevents Ca2+ release from sarcoplasmic reticulum by blocking RYR1 channels.

Q9. What is the recommended defibrillation sequence and energy levels?

Single biphasic shock (120-200J; manufacturer-specific) → immediate CPR resumption (do NOT pulse check) → 2 minutes CPR → rhythm check. If VF persists: shock → CPR. Epinephrine 1 mg IV after 2nd shock. Amiodarone 300 mg IV after 3rd shock. Internal defibrillation (open chest): start at 10J, increase as needed.

Q10. When should amiodarone be given during cardiac arrest?

After the 3rd failed defibrillation attempt in refractory VF or pulseless VT. Dose: 300 mg IV rapid bolus during arrest, then 150 mg supplements as needed. Maximum 2g/day. It improves survival to hospital admission (3 randomized trials) but has not shown survival to discharge benefit. Lidocaine 1-1.5 mg/kg is the alternative if amiodarone is unavailable.

Q11. ETCO2 drops suddenly to zero during surgery. What is your differential?

The ABCDE approach: (A) Oesophageal intubation / tube displacement, (B) Circuit disconnection, (C) Cardiac arrest / massive pulmonary embolism (no blood reaching lungs), (D) Massive air embolism. First check patient (is pulse present?), check airway, check circuit. ETCO2 also correlates with CPR quality - a rising ETCO2 during CPR indicates improving cardiac output.

Q12. How does CPR differ in a prone-positioned patient?

Per 2023 ESAIC guidelines: place defibrillator pads at T7 (posterior) and right shoulder (anterior). Compressions are applied at the same position as standard (lower third of sternum against the table). Do not routinely turn the patient supine unless compressions are definitively ineffective - repositioning wastes critical time.

Q13. What is TTM and when is it indicated post-ROSC?

Targeted Temperature Management at 32-36°C for 24 hours in comatose patients (those not following commands) after ROSC. Reduces secondary neurological injury from reperfusion. Do NOT allow hyperthermia. Monitor temperature continuously. Accompany with EEG monitoring (detect subclinical seizures), brain CT, and normoglycemia. Neuroprognostication should not occur before 48-72 hours post-arrest.

Q14. Can DNAR orders be automatically overridden in the OT?

No. This is a common misconception - 60% of anesthesiologists erroneously believe this. DNAR must be reconsidered, not abandoned in the perioperative period. Anesthesiologist must discuss with patient, document the agreement, and communicate with the full OT team preoperatively. Advance directives are legally binding. Courts have awarded damages when DNAR was overridden without consent.

Q15. What is the role of TEE during cardiac arrest in the OT?

TEE is the gold standard intraoperative diagnostic tool during cardiac arrest. It can identify: new RWMA (myocardial infarction), pericardial effusion/tamponade, right heart failure (PE), hypovolemia (empty heart), massive air embolism, and the adequacy of compressions - all without interrupting CPR. The 2023 ESAIC guidelines support its use in the OT setting.

Summary Framework for Exam

Cardiac Arrest in OT
│
├── RECOGNIZE (< 10 sec): Monitor loss, no pulse
│
├── CALL FOR HELP + START CPR (100-120/min, 5-6 cm)
│
├── DEFIBRILLATOR ON → Shockable? → Shock + CPR
│                                ↓ Non-shockable?
│                              CPR + Epinephrine
│
├── FIX THE CAUSE (H's & T's + OT-specific)
│   ├── Airway failure → Reoxygenate, eFONA
│   ├── Anaphylaxis → Epinephrine IV + fluids
│   ├── LAST → Lipid emulsion 20%
│   ├── Total spinal → Airway + vasopressors
│   ├── MH → Dantrolene + cooling
│   ├── VAE → Durant maneuver + O2
│   ├── Tension PTx → Needle decompression
│   ├── Tamponade → Pericardiocentesis
│   └── Hyperkalemia → Ca2+, bicarb, insulin
│
└── POST-ROSC → TTM (if comatose), STEMI? → Cath lab
                 SpO2 92-98%, PaCO2 35-45, MAP >65

"Remember - in the OT, cardiac arrest is different from the street. You know the cause, you have the team, you have the drugs. What you need is a calm, systematic approach and a team that communicates. Practice the drills, know the algorithms, and never let panic override protocol. That is what separates a good anesthesiologist from a great one."

Key References:

Barash's Clinical Anesthesia 9e, Chapter 58 (pp. 4896-4948)
Miller's Anesthesia 10e (pp. 634, 6127, 1973)
Hinkelbein J et al. "Cardiac arrest in the perioperative period: a consensus guideline." Eur J Anaesthesiol. 2023 Oct (PMID: 37218626) - ESAIC/ESTES Practice Guideline
AHA 2020 Guidelines for CPR and ECC (Circulation. 2020;142:S366-S468)
ASRA Local Anesthetic Systemic Toxicity Checklist (2020)
Morgan & Mikhail's Clinical Anesthesiology 7e

create me a ppt on differences between the 10th edition millers anaesthesia textbook to 9th ed millers - and explain to me the changes with reasons

Reading File

Finding Sources

Searching the Web

Miller's Anesthesia 10th edition vs 9th edition new chapters changes updates 2025

Reading File

Reading Web Page

https://inspectioncopy.elsevier.com/book/details/97803239359…

Finding Sources

Searching the Web

Miller's Anesthesia 9th edition table of contents chapters list Gropper 2020

Reading Web Page

https://www.us.elsevierhealth.com/millers-anesthesia-2-volum…

Reading Web Page

https://shop.elsevier.com/books/millers-anesthesia-2-volume-…

Running Command

mkdir -p /home/daytona/workspace/millers-pptx && ls /home/daytona/workspace/millers-pptx/

Writing File

~/millers-pptx/build.js

const pptxgen = require("pptxgenjs");

const pres = new pptxgen();
pres.layout = "LAYOUT_WIDE"; // 13.3" x 7.5"
pres.title = "Miller's Anesthesia: 10th vs 9th Edition - Key Changes";
pres.author = "Orris Medical Education";

// ─── COLOUR PALETTE ───────────────────────────────────────────────────────────
const C = {
  navy:    "0A1628",   // dominant dark
  blue:    "1565C0",   // primary accent
  teal:    "00838F",   // secondary accent
  gold:    "F9A825",   // highlight accent
  white:   "FFFFFF",
  ltgray:  "F0F4F8",
  midgray: "90A4AE",
  darkgray:"37474F",
  green:   "2E7D32",
  red:     "B71C1C",
  orange:  "E65100",
  purple:  "6A1B9A",
};

// ─── HELPERS ──────────────────────────────────────────────────────────────────
function titleSlide(title, subtitle) {
  const s = pres.addSlide();
  // full dark background
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:"100%", h:"100%", fill:{color:C.navy} });
  // gold accent bar
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:0.08, h:"100%", fill:{color:C.gold} });
  // decorative horizontal rule
  s.addShape(pres.ShapeType.rect, { x:0.5, y:4.1, w:12.3, h:0.04, fill:{color:C.gold} });
  // "MILLER'S ANESTHESIA" label
  s.addText("MILLER'S ANESTHESIA", {
    x:0.6, y:0.9, w:12, h:0.6,
    fontSize:13, bold:true, color:C.gold, fontFace:"Calibri", charSpacing:8,
  });
  // main title
  s.addText(title, {
    x:0.6, y:1.5, w:12, h:2.2,
    fontSize:44, bold:true, color:C.white, fontFace:"Calibri", lineSpacingMultiple:1.1,
  });
  // subtitle
  s.addText(subtitle, {
    x:0.6, y:4.3, w:12, h:0.7,
    fontSize:22, color:C.midgray, fontFace:"Calibri", italic:true,
  });
  // edition badges
  s.addShape(pres.ShapeType.roundRect, { x:0.6, y:5.4, w:2.8, h:0.7, fill:{color:C.red}, rectRadius:0.1 });
  s.addText("9th Edition  2019", { x:0.6, y:5.4, w:2.8, h:0.7, fontSize:14, bold:true, color:C.white, align:"center", valign:"middle" });
  s.addShape(pres.ShapeType.rect, { x:3.6, y:5.6, w:1.0, h:0.25, fill:{color:C.gold} });
  s.addText("→", { x:4.2, y:5.35, w:0.6, h:0.8, fontSize:30, color:C.gold, align:"center", valign:"middle" });
  s.addShape(pres.ShapeType.roundRect, { x:5.0, y:5.4, w:2.8, h:0.7, fill:{color:C.green}, rectRadius:0.1 });
  s.addText("10th Edition  2024", { x:5.0, y:5.4, w:2.8, h:0.7, fontSize:14, bold:true, color:C.white, align:"center", valign:"middle" });
  // footer
  s.addText("A comprehensive comparison for residents & anesthesiologists", {
    x:0.6, y:6.7, w:12, h:0.5, fontSize:11, color:C.midgray, fontFace:"Calibri", italic:true,
  });
  return s;
}

function sectionDivider(sectionNum, sectionTitle, subtitle) {
  const s = pres.addSlide();
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:"100%", h:"100%", fill:{color:C.blue} });
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:"100%", h:0.08, fill:{color:C.gold} });
  s.addShape(pres.ShapeType.rect, { x:0, y:7.42, w:"100%", h:0.08, fill:{color:C.gold} });
  // section number
  s.addText(`SECTION ${sectionNum}`, {
    x:0.6, y:1.2, w:12, h:0.6,
    fontSize:13, bold:true, color:C.gold, fontFace:"Calibri", charSpacing:8,
  });
  s.addText(sectionTitle, {
    x:0.6, y:1.9, w:12, h:2.0,
    fontSize:42, bold:true, color:C.white, fontFace:"Calibri",
  });
  s.addShape(pres.ShapeType.rect, { x:0.6, y:4.2, w:3.5, h:0.05, fill:{color:C.gold} });
  s.addText(subtitle, {
    x:0.6, y:4.5, w:11, h:0.8,
    fontSize:18, color:"D1E8FF", fontFace:"Calibri", italic:true,
  });
  return s;
}

function contentSlide(title, accentColor, items, notes) {
  // items: array of {label, text, color?}  OR  array of strings for bullets
  const s = pres.addSlide();
  // light background
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:"100%", h:"100%", fill:{color:C.ltgray} });
  // left accent bar
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:0.06, h:"100%", fill:{color:accentColor} });
  // title bar
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:"100%", h:1.1, fill:{color:accentColor} });
  s.addText(title, {
    x:0.25, y:0.08, w:12.8, h:0.9,
    fontSize:26, bold:true, color:C.white, fontFace:"Calibri", valign:"middle", margin:0,
  });
  // content area
  if (notes) {
    s.addText(notes, {
      x:0.25, y:6.7, w:13, h:0.55,
      fontSize:10, color:C.midgray, fontFace:"Calibri", italic:true,
    });
  }
  return s;
}

function addBulletBox(slide, x, y, w, h, title, bullets, titleColor, bgColor) {
  slide.addShape(pres.ShapeType.roundRect, { x, y, w, h, fill:{color:bgColor||C.white}, line:{color:C.midgray, width:0.5}, rectRadius:0.12 });
  slide.addText(title, {
    x:x+0.12, y:y+0.06, w:w-0.24, h:0.38,
    fontSize:13, bold:true, color:titleColor||C.blue, fontFace:"Calibri", margin:0,
  });
  const bulletItems = bullets.map((b,i) => ({
    text: b,
    options: { bullet:true, breakLine: i < bullets.length-1, fontSize:11.5, color:C.darkgray, fontFace:"Calibri" }
  }));
  slide.addText(bulletItems, {
    x:x+0.12, y:y+0.48, w:w-0.24, h:h-0.58,
    fontFace:"Calibri",
  });
}

function compareBoxes(slide, leftTitle, leftItems, rightTitle, rightItems, leftColor, rightColor) {
  // VS layout: left half = old, right half = new
  addBulletBox(slide, 0.25, 1.25, 6.1, 5.8, `9th Ed — ${leftTitle}`, leftItems, leftColor||C.red, C.white);
  addBulletBox(slide, 6.95, 1.25, 6.1, 5.8, `10th Ed — ${rightTitle}`, rightItems, rightColor||C.green, C.white);
  // arrow between
  slide.addText("➜", { x:6.15, y:3.7, w:0.7, h:0.8, fontSize:28, color:C.gold, align:"center", valign:"middle" });
}

// ══════════════════════════════════════════════════════════════════════════════
//  SLIDE 1 — TITLE
// ══════════════════════════════════════════════════════════════════════════════
titleSlide(
  "10th vs 9th Edition\nKey Changes & Why They Matter",
  "A Structured Comparison for Residents, Trainees & Attendings"
);

// ══════════════════════════════════════════════════════════════════════════════
//  SLIDE 2 — OVERVIEW AT-A-GLANCE
// ══════════════════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:"100%", h:"100%", fill:{color:C.navy} });
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:0.06, h:"100%", fill:{color:C.gold} });
  s.addText("AT A GLANCE — SIDE BY SIDE", {
    x:0.25, y:0.12, w:13, h:0.7,
    fontSize:22, bold:true, color:C.gold, fontFace:"Calibri", charSpacing:4,
  });
  // left panel
  s.addShape(pres.ShapeType.roundRect, { x:0.25, y:1.0, w:6.1, h:6.0, fill:{color:"1A2744"}, rectRadius:0.15 });
  s.addShape(pres.ShapeType.roundRect, { x:0.35, y:1.0, w:6.0, h:0.5, fill:{color:C.red}, rectRadius:0.1 });
  s.addText("9th EDITION  (2019)", { x:0.35, y:1.0, w:6.0, h:0.5, fontSize:15, bold:true, color:C.white, align:"center", valign:"middle" });
  const col9 = [
    "Published: 2019",
    "Editors: Gropper, Miller, Eriksson, Fleisher,\n  Wiener-Kronish, Cohen, Leslie",
    "Total Chapters: ~90 chapters",
    "4 New Chapters (vs 8th ed):",
    "  • Extreme Environments (High/Low Pressure)",
    "  • Immediate & Long-Term Complications",
    "  • Clinical Research",
    "  • Interpreting Medical Literature",
    "Focus: neurotoxicity, palliation,\n  sleep/wake disorders",
    "Echocardiography: Ch 37 (standard echo only)",
    "No dedicated Immune System chapter",
    "No Emergency Preparedness chapter",
    "Streamlined several topics vs 8th ed",
  ];
  const col9Items = col9.map((t,i)=>({text:t, options:{bullet:i>2&&i<9, breakLine:i<col9.length-1, fontSize:11.5, color:i===0||i===1||i===2?C.gold:C.white, bold:i===0||i===2, fontFace:"Calibri"}}));
  s.addText(col9Items, { x:0.45, y:1.62, w:5.8, h:5.2, fontFace:"Calibri" });

  // right panel
  s.addShape(pres.ShapeType.roundRect, { x:6.95, y:1.0, w:6.1, h:6.0, fill:{color:"1A2744"}, rectRadius:0.15 });
  s.addShape(pres.ShapeType.roundRect, { x:7.05, y:1.0, w:6.0, h:0.5, fill:{color:C.green}, rectRadius:0.1 });
  s.addText("10th EDITION  (2024)", { x:7.05, y:1.0, w:6.0, h:0.5, fontSize:15, bold:true, color:C.white, align:"center", valign:"middle" });
  const col10 = [
    "Published: 2024",
    "Editors: Gropper, Eriksson, Fleisher, Cohen,\n  Leslie + New: Oluwaseun Johnson-Akeju",
    "Total Chapters: ~87 chapters",
    "2 Brand-New Chapters:",
    "  • Immune System & Anesthetic Management",
    "  • Emergency Preparedness in Healthcare",
    "Major Expansions:",
    "  • POCUS (point-of-care ultrasound)",
    "  • COVID-19 & infection control protocols",
    "  • Sustainability in anesthesia",
    "  • Global health equity",
    "  • Pediatric / neonatal / congenital cardiac",
    "  • Perioperative neurocognitive disorders",
    "New section structure: more logical flow",
  ];
  const col10Items = col10.map((t,i)=>({text:t, options:{bullet:i>2&&i<14, breakLine:i<col10.length-1, fontSize:11.5, color:i===0||i===1||i===2?C.gold:C.white, bold:i===0||i===2||i===6, fontFace:"Calibri"}}));
  s.addText(col10Items, { x:7.1, y:1.62, w:5.8, h:5.2, fontFace:"Calibri" });

  // vs badge
  s.addShape(pres.ShapeType.roundRect, { x:6.3, y:3.7, w:0.72, h:0.72, fill:{color:C.gold}, rectRadius:0.36 });
  s.addText("VS", { x:6.3, y:3.7, w:0.72, h:0.72, fontSize:16, bold:true, color:C.navy, align:"center", valign:"middle" });
}

// ══════════════════════════════════════════════════════════════════════════════
// SECTION 1 — NEW CHAPTERS
// ══════════════════════════════════════════════════════════════════════════════
sectionDivider(1, "Brand-New Chapters", "Two entirely new chapters added to the 10th edition — reflecting the evolution of the specialty");

// Slide: New Chapter 1 — Immune System
{
  const s = pres.addSlide();
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:"100%", h:"100%", fill:{color:C.ltgray} });
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:"100%", h:1.15, fill:{color:C.purple} });
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:0.06, h:"100%", fill:{color:C.purple} });
  s.addText("NEW CHAPTER  |  Chapter 26", { x:0.25, y:0.05, w:13, h:0.35, fontSize:12, color:"D1C4E9", bold:true, charSpacing:5, margin:0 });
  s.addText("The Immune System: Implications for Anesthetic Management", {
    x:0.25, y:0.38, w:13, h:0.7, fontSize:22, bold:true, color:C.white, fontFace:"Calibri", margin:0,
  });

  // Why added box
  s.addShape(pres.ShapeType.roundRect, { x:0.25, y:1.3, w:6.2, h:2.8, fill:{color:"EDE7F6"}, rectRadius:0.12, line:{color:C.purple, width:1} });
  s.addText("WHY THIS CHAPTER WAS ADDED", { x:0.4, y:1.38, w:5.9, h:0.4, fontSize:12, bold:true, color:C.purple, margin:0 });
  s.addText([
    { text: "COVID-19 pandemic", options:{bold:true, breakLine:true} },
    { text: " revealed critical gaps in understanding how anesthetics modulate immune function — viral pneumonia patients required unique anesthetic & ICU approaches.\n\n", options:{breakLine:false} },
    { text: "Growing evidence", options:{bold:true, breakLine:true} },
    { text: " that volatile agents, propofol, and opioids exert profound immunomodulatory effects affecting infection, cancer recurrence, and organ rejection.", options:{} },
  ], { x:0.4, y:1.82, w:5.9, h:2.15, fontSize:11.5, color:C.darkgray, fontFace:"Calibri" });

  // What it covers
  s.addShape(pres.ShapeType.roundRect, { x:6.7, y:1.3, w:6.35, h:2.8, fill:{color:"EDE7F6"}, rectRadius:0.12, line:{color:C.purple, width:1} });
  s.addText("WHAT IT COVERS", { x:6.85, y:1.38, w:6.0, h:0.4, fontSize:12, bold:true, color:C.purple, margin:0 });
  const immuneItems = [
    "Innate vs adaptive immunity — anesthesia effects",
    "Volatile anesthetics (sevoflurane, isoflurane): anti-inflammatory effects via cytokine modulation",
    "Propofol: immunosuppressive properties — clinical relevance in oncology patients",
    "Opioids (morphine, fentanyl): immune suppression — links to surgical site infections",
    "COVID-19 protocols: airway management, PPE, aerosol-generating procedures",
    "Perioperative infection control in high-risk patients",
    "Implications for organ transplantation & cancer surgery",
  ];
  s.addText(immuneItems.map((t,i)=>({text:t, options:{bullet:true, breakLine:i<immuneItems.length-1, fontSize:11, color:C.darkgray, fontFace:"Calibri"}})), {
    x:6.85, y:1.82, w:6.0, h:2.15,
  });

  // Clinical impact
  s.addShape(pres.ShapeType.roundRect, { x:0.25, y:4.25, w:12.8, h:2.8, fill:{color:C.purple}, rectRadius:0.12 });
  s.addText("CLINICAL IMPACT FOR THE ANESTHESIOLOGIST", { x:0.45, y:4.35, w:12.4, h:0.4, fontSize:13, bold:true, color:C.gold, margin:0 });
  const impactItems = [
    "Cancer patients: choice of anesthetic technique (regional vs. GA) may affect tumor recurrence — this chapter synthesizes the evidence",
    "Transplant patients: understanding immunosuppression interactions with anesthetic drugs",
    "Sepsis & critical illness: anesthetic immunomodulation in ICU patients",
    "Post-COVID surgical patients: modified airway & ventilation protocols",
  ];
  s.addText(impactItems.map((t,i)=>({text:t, options:{bullet:true, breakLine:i<impactItems.length-1, fontSize:11.5, color:C.white, fontFace:"Calibri"}})), {
    x:0.45, y:4.78, w:12.4, h:2.15,
  });
}

// Slide: New Chapter 2 — Emergency Preparedness
{
  const s = pres.addSlide();
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:"100%", h:"100%", fill:{color:C.ltgray} });
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:"100%", h:1.15, fill:{color:C.orange} });
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:0.06, h:"100%", fill:{color:C.orange} });
  s.addText("NEW CHAPTER  |  Chapter 85", { x:0.25, y:0.05, w:13, h:0.35, fontSize:12, color:"FFE0B2", bold:true, charSpacing:5, margin:0 });
  s.addText("Emergency Preparedness in Healthcare", {
    x:0.25, y:0.38, w:13, h:0.7, fontSize:26, bold:true, color:C.white, fontFace:"Calibri", margin:0,
  });

  s.addShape(pres.ShapeType.roundRect, { x:0.25, y:1.3, w:6.2, h:2.75, fill:{color:"FFF3E0"}, rectRadius:0.12, line:{color:C.orange, width:1} });
  s.addText("WHY THIS CHAPTER WAS ADDED", { x:0.4, y:1.38, w:5.9, h:0.4, fontSize:12, bold:true, color:C.orange, margin:0 });
  s.addText([
    { text: "COVID-19 pandemic (2020-2022)", options:{bold:true, breakLine:true} },
    { text: " exposed catastrophic gaps in hospital preparedness — supply chains, surge capacity, PPE protocols, and staff safety.\n\n", options:{} },
    { text: "Anesthesiologists", options:{bold:true} },
    { text: " are de facto first responders in mass-casualty, biological, and chemical events — requiring formalized training not previously in the text.", options:{} },
  ], { x:0.4, y:1.82, w:5.9, h:2.1, fontSize:11.5, color:C.darkgray, fontFace:"Calibri" });

  s.addShape(pres.ShapeType.roundRect, { x:6.7, y:1.3, w:6.35, h:2.75, fill:{color:"FFF3E0"}, rectRadius:0.12, line:{color:C.orange, width:1} });
  s.addText("WHAT IT COVERS", { x:6.85, y:1.38, w:6.0, h:0.4, fontSize:12, bold:true, color:C.orange, margin:0 });
  const prepItems = [
    "Hospital incident command systems (HICS)",
    "Mass-casualty incident (MCI) triage & anesthetic management",
    "Pandemic protocols: COVID-19 lessons for future outbreaks",
    "Chemical & biological warfare agent exposure",
    "PPE protocols & donning/doffing for aerosol-generating procedures",
    "Surge capacity planning for OR & ICU",
    "Psychological resilience & staff support in crises",
    "Communication frameworks during disasters",
  ];
  s.addText(prepItems.map((t,i)=>({text:t, options:{bullet:true, breakLine:i<prepItems.length-1, fontSize:11, color:C.darkgray, fontFace:"Calibri"}})), {
    x:6.85, y:1.82, w:6.0, h:2.1,
  });

  s.addShape(pres.ShapeType.roundRect, { x:0.25, y:4.2, w:12.8, h:2.85, fill:{color:C.orange}, rectRadius:0.12 });
  s.addText("WHY THIS MATTERS TO YOU AS AN ANESTHESIOLOGIST", { x:0.45, y:4.3, w:12.4, h:0.4, fontSize:13, bold:true, color:C.white, margin:0 });
  s.addText([
    { text: "Pre-COVID: ", options:{bold:true} },
    { text: "Emergency preparedness was scattered across surgical texts, disaster medicine manuals, and institution-specific protocols. No single anesthesia resource addressed it comprehensively.\n\n", options:{} },
    { text: "Post-COVID: ", options:{bold:true} },
    { text: "This chapter consolidates everything — from respiratory protection to psychological safety of anesthesia providers — making it exam-relevant and operationally essential.", options:{} },
  ], { x:0.45, y:4.75, w:12.4, h:2.15, fontSize:11.5, color:C.white, fontFace:"Calibri" });
}

// ══════════════════════════════════════════════════════════════════════════════
// SECTION 2 — STRUCTURAL CHANGES
// ══════════════════════════════════════════════════════════════════════════════
sectionDivider(2, "Structural & Editorial Changes", "How the book was reorganized — and why it matters for how you learn");

// Chapter structure comparison
{
  const s = pres.addSlide();
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:"100%", h:"100%", fill:{color:C.ltgray} });
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:"100%", h:1.1, fill:{color:C.teal} });
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:0.06, h:"100%", fill:{color:C.teal} });
  s.addText("Chapter Structure & Organization", { x:0.25, y:0.15, w:13, h:0.75, fontSize:26, bold:true, color:C.white, margin:0 });

  // Table header
  const headers = ["Feature", "9th Edition (2019)", "10th Edition (2024)", "Reason for Change"];
  const rows = [
    ["Total chapters", "~90 chapters", "~87 chapters", "Redundant topics merged; cleaner flow"],
    ["Echocardiography", "Ch 37: Perioperative Echocardiography only", "Ch 33: Echocardiography AND POCUS combined", "POCUS exploded in clinical practice post-2019"],
    ["Neurologic monitoring", "Ch 39 & 40 (two chapters — Neurologic Monitoring + Depth of Anesthesia)", "Ch 35 & 36 (renamed, updated, restructured)", "Reflects new BIS/EEG data and awareness monitoring guidelines"],
    ["Immune chapter", "None", "Ch 26 — dedicated immune chapter (NEW)", "COVID-19 and cancer anesthesia evidence base"],
    ["Emergency preparedness", "Ch 68 — Disasters (limited)", "Ch 85 — Full Emergency Preparedness chapter (NEW)", "Pandemic lessons; anesthesiologist role in disaster response"],
    ["Pediatric section", "4 chapters (76-79)", "Expanded pediatric coverage (5 chapters 70-75)", "Growing complexity of pediatric subspecialties"],
    ["Post-op cognitive issues", "Ch 83 — 'Cognitive Dysfunction & Long-Term Complications'", "Ch 78 — 'Perioperative Neurocognitive Disorders' (renamed)", "2018 renaming consensus (NCD/POCD replaced by PACD/POCD/PODS terminology)"],
    ["Section numbering", "8 sections", "8 sections but reordered", "Better logical flow from basic to clinical science"],
  ];

  const colW = [2.0, 3.1, 3.1, 4.6];
  const colX = [0.2, 2.22, 5.34, 8.46];
  const rowH = 0.55;
  const startY = 1.2;

  // header row
  headers.forEach((h,ci) => {
    s.addShape(pres.ShapeType.rect, { x:colX[ci], y:startY, w:colW[ci], h:0.5, fill:{color:C.teal} });
    s.addText(h, { x:colX[ci]+0.05, y:startY, w:colW[ci]-0.1, h:0.5, fontSize:11, bold:true, color:C.white, valign:"middle", margin:0 });
  });
  // data rows
  rows.forEach((row, ri) => {
    const y = startY + 0.5 + ri * rowH;
    row.forEach((cell, ci) => {
      const bg = ri % 2 === 0 ? C.white : "E8F4FD";
      s.addShape(pres.ShapeType.rect, { x:colX[ci], y, w:colW[ci], h:rowH, fill:{color:bg}, line:{color:"D0D7DE", width:0.3} });
      s.addText(cell, { x:colX[ci]+0.06, y:y+0.03, w:colW[ci]-0.12, h:rowH-0.06, fontSize:9.5, color:C.darkgray, valign:"middle", shrinkText:true });
    });
  });
}

// ══════════════════════════════════════════════════════════════════════════════
// SECTION 3 — POCUS
// ══════════════════════════════════════════════════════════════════════════════
sectionDivider(3, "POCUS — Point-of-Care Ultrasound", "The single biggest technology update in the 10th edition");

{
  const s = pres.addSlide();
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:"100%", h:"100%", fill:{color:C.ltgray} });
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:"100%", h:1.1, fill:{color:C.teal} });
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:0.06, h:"100%", fill:{color:C.teal} });
  s.addText("POCUS: From Echo to Bedside Ultrasound — Chapter 33", { x:0.25, y:0.15, w:13, h:0.75, fontSize:24, bold:true, color:C.white, margin:0 });

  // left = 9th
  s.addShape(pres.ShapeType.roundRect, { x:0.25, y:1.2, w:6.1, h:5.9, fill:{color:C.white}, rectRadius:0.12, line:{color:C.red, width:1.5} });
  s.addShape(pres.ShapeType.roundRect, { x:0.25, y:1.2, w:6.1, h:0.5, fill:{color:C.red}, rectRadius:0.1 });
  s.addText("9th Edition — Ch 37: Perioperative Echocardiography", { x:0.35, y:1.2, w:5.9, h:0.5, fontSize:11.5, bold:true, color:C.white, align:"center", valign:"middle" });
  const items9 = [
    "Focused on TEE (transesophageal echocardiography)",
    "TTE (transthoracic) briefly covered",
    "No dedicated POCUS section",
    "Ultrasound for regional anesthesia in a separate chapter",
    "No lung ultrasound protocols",
    "No vascular access ultrasound in this chapter",
    "Limited guidance on POCUS in critical care",
    "Basic perioperative echo views described",
  ];
  s.addText(items9.map((t,i)=>({text:t, options:{bullet:true, breakLine:i<items9.length-1, fontSize:11, color:C.darkgray, fontFace:"Calibri"}})), {
    x:0.4, y:1.82, w:5.8, h:5.1,
  });

  // VS
  s.addShape(pres.ShapeType.roundRect, { x:6.28, y:3.5, w:0.74, h:0.74, fill:{color:C.gold}, rectRadius:0.37 });
  s.addText("VS", { x:6.28, y:3.5, w:0.74, h:0.74, fontSize:16, bold:true, color:C.navy, align:"center", valign:"middle" });

  // right = 10th
  s.addShape(pres.ShapeType.roundRect, { x:7.0, y:1.2, w:6.1, h:5.9, fill:{color:C.white}, rectRadius:0.12, line:{color:C.green, width:1.5} });
  s.addShape(pres.ShapeType.roundRect, { x:7.0, y:1.2, w:6.1, h:0.5, fill:{color:C.green}, rectRadius:0.1 });
  s.addText("10th Edition — Ch 33: Echo AND POCUS", { x:7.1, y:1.2, w:5.9, h:0.5, fontSize:11.5, bold:true, color:C.white, align:"center", valign:"middle" });
  const items10 = [
    "Full TEE & TTE (transthoracic) coverage with updated views",
    "DEDICATED POCUS section — adults AND pediatrics",
    "Lung ultrasound: B-lines, pneumothorax, effusion protocols",
    "Vascular access POCUS — arterial, venous",
    "POCUS in cardiac arrest (FEEL protocol)",
    "Focused abdominal & renal POCUS",
    "Pediatric POCUS applications expanded",
    "POCUS image acquisition technique & pitfalls",
    "Integration with regional anesthesia workflows",
  ];
  s.addText(items10.map((t,i)=>({text:t, options:{bullet:true, breakLine:i<items10.length-1, fontSize:11, color:C.darkgray, fontFace:"Calibri", bold:i===1||i===4}})), {
    x:7.15, y:1.82, w:5.8, h:5.1,
  });
}

// ══════════════════════════════════════════════════════════════════════════════
// SECTION 4 — KEY CLINICAL CHAPTER UPDATES
// ══════════════════════════════════════════════════════════════════════════════
sectionDivider(4, "Major Clinical Chapter Updates", "Updated guidelines, new evidence, and expanded clinical content");

// Neurocognitive disorders
{
  const s = contentSlide("Perioperative Neurocognitive Disorders — Ch 78 (was Ch 83)", C.blue);
  compareBoxes(s,
    "Cognitive Dysfunction\n& Long-Term Complications",
    [
      "Terminology: POCD (Post-Op Cognitive Dysfunction) — outdated but used",
      "Combined postoperative complications into one chapter",
      "Limited mechanistic detail on neuroinflammation",
      "No standardized diagnostic criteria presented",
      "Minimal discussion of biomarkers",
      "Delirium covered briefly",
    ],
    "Perioperative\nNeurocognitive Disorders",
    [
      "UPDATED terminology per 2018 consensus: PACD (Acute) / POCD (Delayed) / PODS (Delayed onset) / Periop NCD",
      "Dedicated separate chapter — expanded substantially",
      "Neuroinflammation: IL-6, TNF-α, microglial activation mechanisms",
      "EEG-based monitoring for suppression and burst-suppression",
      "Biomarkers: GFAP, NfL, tau, S100β perioperative role",
      "Prevention: BIS-guided anaesthesia reduces POCD incidence",
      "Dexmedetomidine evidence for PACD prevention in ICU",
    ],
    C.red, C.green
  );
}

// Airway management
{
  const s = contentSlide("Airway Management in the Adult — Ch 40 (was Ch 44)", C.navy);
  compareBoxes(s,
    "Airway Management\n(9th Edition)",
    [
      "DAS/ASA difficult airway algorithm (2013 versions)",
      "Videolaryngoscopy mentioned but not front-and-centre",
      "Supraglottic airways: LMA, i-gel covered",
      "CICO concept included but not emphasized",
      "Cricothyroidotomy: standard surgical technique",
      "Awake intubation: fiberoptic as gold standard",
      "Limited coverage of high-flow nasal oxygen (HFNO)",
    ],
    "Airway Management\n(10th Edition)",
    [
      "Updated DAS (2015) & ASA (2022) difficult airway guidelines fully incorporated",
      "Videolaryngoscopy: prominent role — first-line in many scenarios",
      "eFONA (emergency front-of-neck access) expanded with scalpel-bougie technique",
      "HFNO (high-flow nasal oxygen) — apneic oxygenation protocols",
      "THRIVE (Transnasal Humidified Rapid-Insufflation Ventilatory Exchange) covered",
      "Awake intubation: combined VL + FOB techniques",
      "COVID-19 airway modifications (donning, closed-circuit techniques)",
    ],
    C.red, C.green
  );
}

// Pharmacology — opioids & NMB
{
  const s = contentSlide("Pharmacology Updates — Opioids, NMBDs & Intravenous Anesthetics", C.teal);
  compareBoxes(s,
    "9th Edition\nPharmacology Coverage",
    [
      "Opioid crisis mentioned but limited perioperative guidance",
      "Sugammadex: established but dosing controversies unresolved",
      "Remimazolam: mentioned only",
      "Dexmedetomidine: limited perioperative role described",
      "IV drug delivery: TIVA algorithms present",
      "No specific opioid-sparing multimodal analgesia framework",
    ],
    "10th Edition\nPharmacology Coverage",
    [
      "Opioid-sparing / opioid-free anesthesia (OFA) — expanded framework",
      "Sugammadex: updated dosing, reversal at profound block, safety evidence",
      "Remimazolam: full coverage — pharmacokinetics, clinical use, reversal (flumazenil)",
      "Dexmedetomidine: expanded role — ICU sedation, opioid sparing, PACD prevention",
      "TIVA: updated TCI models (Eleveld propofol, Minto remifentanil)",
      "Multimodal analgesia: ketamine, dexamethasone, lidocaine infusion, NSAIDs",
      "Opioid-induced hyperalgesia — mechanisms and clinical relevance",
    ],
    C.red, C.green
  );
}

// ══════════════════════════════════════════════════════════════════════════════
// SECTION 5 — NEW CONTENT THEMES
// ══════════════════════════════════════════════════════════════════════════════
sectionDivider(5, "New Content Themes & Topics", "Cross-cutting themes that permeate the entire 10th edition");

// Sustainability + Global health
{
  const s = pres.addSlide();
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:"100%", h:"100%", fill:{color:C.ltgray} });
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:"100%", h:1.1, fill:{color:C.green} });
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:0.06, h:"100%", fill:{color:C.green} });
  s.addText("Two Major New Themes: Sustainability & Global Health Equity", { x:0.25, y:0.15, w:13, h:0.75, fontSize:22, bold:true, color:C.white, margin:0 });

  // Box 1 — Sustainability
  s.addShape(pres.ShapeType.roundRect, { x:0.25, y:1.2, w:6.0, h:5.95, fill:{color:C.white}, rectRadius:0.12, line:{color:C.green, width:1.5} });
  s.addShape(pres.ShapeType.rect, { x:0.25, y:1.2, w:6.0, h:0.5, fill:{color:C.green} });
  s.addText("🌱 SUSTAINABILITY IN ANESTHESIA", { x:0.35, y:1.2, w:5.8, h:0.5, fontSize:13, bold:true, color:C.white, align:"center", valign:"middle" });
  const sustItems = [
    "NOT in 9th edition — entirely new content",
    "Volatile anesthetic agents contribute to greenhouse gas emissions:",
    "  • Desflurane: GWP 2540× CO₂ over 100 years",
    "  • Sevoflurane: GWP 130× CO₂",
    "  • Isoflurane: GWP 510× CO₂",
    "Desflurane: many centres globally discontinuing due to climate impact",
    "Low-flow anesthesia techniques to reduce agent consumption",
    "TIVA (propofol) as a more environmentally friendly alternative",
    "Nitrous oxide: stratospheric ozone depletion — clinical re-evaluation",
    "Green anesthesia movement: WFSA + ASA sustainability initiatives",
    "Medical waste reduction protocols in OR",
  ];
  s.addText(sustItems.map((t,i)=>({text:t, options:{bullet:i>0, breakLine:i<sustItems.length-1, fontSize:10.5, color:C.darkgray, fontFace:"Calibri", bold:i===0||i===6}})), {
    x:0.4, y:1.82, w:5.7, h:5.2,
  });

  // Box 2 — Global health
  s.addShape(pres.ShapeType.roundRect, { x:6.95, y:1.2, w:6.1, h:5.95, fill:{color:C.white}, rectRadius:0.12, line:{color:C.teal, width:1.5} });
  s.addShape(pres.ShapeType.rect, { x:6.95, y:1.2, w:6.1, h:0.5, fill:{color:C.teal} });
  s.addText("🌍 GLOBAL HEALTH EQUITY", { x:7.05, y:1.2, w:5.9, h:0.5, fontSize:13, bold:true, color:C.white, align:"center", valign:"middle" });
  const globalItems = [
    "Significantly expanded from 9th edition",
    "The global surgical burden: 5 billion people lack access to safe surgery",
    "Lancet Commission on Global Surgery — anesthesia as a public health priority",
    "Low/middle income countries (LMIC):",
    "  • Ketamine as the workhorse anesthetic in resource-limited settings",
    "  • Spinal anesthesia without complex monitoring",
    "  • Oxygen supply challenges and alternatives",
    "Training & capacity building — task-shifting, nurse anesthetists",
    "WHO Global Pulse Oximetry Project",
    "Global disparities in perioperative mortality (maternal mortality esp.)",
    "New editor Johnson-Akeju brings African/global perspective",
  ];
  s.addText(globalItems.map((t,i)=>({text:t, options:{bullet:i>0, breakLine:i<globalItems.length-1, fontSize:10.5, color:C.darkgray, fontFace:"Calibri", bold:i===0||i===10}})), {
    x:7.1, y:1.82, w:5.8, h:5.2,
  });
}

// COVID-19 & Infection Control
{
  const s = pres.addSlide();
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:"100%", h:"100%", fill:{color:C.ltgray} });
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:"100%", h:1.1, fill:{color:C.navy} });
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:0.06, h:"100%", fill:{color:C.gold} });
  s.addText("COVID-19 Impact on Anesthetic Practice — New Content Throughout", { x:0.25, y:0.15, w:13, h:0.75, fontSize:22, bold:true, color:C.white, margin:0 });

  // 3-column grid
  const cols = [
    { x:0.25, title:"Airway\nManagement", color:C.blue, items:[
      "Closed-circuit intubation techniques",
      "N95/FFP3 respirator protocols",
      "Video laryngoscopy as first-line in COVID",
      "Aerosol-generating procedure (AGP) classification",
      "Rapid-sequence intubation modifications",
      "Extubation in COVID — PPE & risk stratification",
    ]},
    { x:4.5, title:"ICU &\nCritical Care", color:C.teal, items:[
      "ARDS management: prone positioning protocols",
      "Awake prone positioning (APP) — novel technique",
      "High-flow nasal oxygen (HFNO) evidence",
      "Non-invasive ventilation in COVID ARDS",
      "Dexamethasone: RECOVERY trial evidence",
      "Anticoagulation in COVID coagulopathy",
    ]},
    { x:8.75, title:"OR Safety &\nInfection Control", color:C.purple, items:[
      "OR negative pressure design considerations",
      "Terminal OR cleaning protocols",
      "PPE donning/doffing algorithms",
      "Elective surgery postponement criteria",
      "Vaccination status and perioperative risk",
      "Post-COVID lung function assessment",
    ]},
  ];
  const bw = 4.0;
  cols.forEach(col => {
    s.addShape(pres.ShapeType.roundRect, { x:col.x, y:1.2, w:bw, h:5.9, fill:{color:C.white}, rectRadius:0.12, line:{color:col.color, width:1.5} });
    s.addShape(pres.ShapeType.rect, { x:col.x, y:1.2, w:bw, h:0.65, fill:{color:col.color} });
    s.addText(col.title, { x:col.x+0.1, y:1.2, w:bw-0.2, h:0.65, fontSize:13, bold:true, color:C.white, align:"center", valign:"middle" });
    s.addText(col.items.map((t,i)=>({text:t, options:{bullet:true, breakLine:i<col.items.length-1, fontSize:11, color:C.darkgray, fontFace:"Calibri"}})), {
      x:col.x+0.15, y:1.95, w:bw-0.3, h:4.95,
    });
  });
  s.addText("9th Edition (published 2019): Pre-COVID — none of this content existed", {
    x:0.25, y:7.1, w:13, h:0.3, fontSize:10, color:C.midgray, italic:true, align:"center",
  });
}

// ══════════════════════════════════════════════════════════════════════════════
// SECTION 6 — SUBSPECIALTY UPDATES
// ══════════════════════════════════════════════════════════════════════════════
sectionDivider(6, "Subspecialty Updates", "Pediatrics, regional, critical care, and special populations");

// Pediatric
{
  const s = contentSlide("Pediatric Anesthesia — Expanded & Restructured (Ch 70-75)", C.blue);
  compareBoxes(s,
    "9th Edition Pediatrics\n(4 chapters: 76-79)",
    [
      "Pediatric Regional: Ch 76",
      "General Pediatric Anesthesia: Ch 77 (broad, single chapter)",
      "Cardiac Surgery Pediatrics: Ch 78",
      "Pediatric & Neonatal ICU: Ch 79",
      "Limited congenital heart disease depth",
      "POCUS in children: minimal coverage",
      "Neonatal physiology: covered in general chapter",
    ],
    "10th Edition Pediatrics\n(5+ chapters: 70-75)",
    [
      "Expanded to 5-6 chapters — significantly more detail",
      "Separate dedicated neonatal anesthesia content",
      "Congenital cardiac anesthesia: greatly expanded",
      "Pediatric POCUS: dedicated section (unique to 10th ed)",
      "Pediatric regional anesthesia: ultrasound-guided techniques front-and-centre",
      "Neonatal physiology & pharmacology: expanded",
      "Paediatric critical care: updated mechanical ventilation protocols",
    ],
    C.red, C.green
  );
}

// Critical care
{
  const s = contentSlide("Critical Care Medicine — Section VII Updates", C.teal);
  compareBoxes(s,
    "9th Edition Critical Care\n(Ch 84-87)",
    [
      "ECMO: Ch 86 — basics covered",
      "CPR/ACLS: AHA 2015 guidelines",
      "Neurocritical care: standard coverage",
      "No specific ARDS protocol integration",
      "Vasopressor protocols: older evidence base",
      "Liberation from mechanical ventilation: standard criteria",
    ],
    "10th Edition Critical Care\n(Ch 79-82)",
    [
      "ECMO: updated with expanded VA-ECMO & VV-ECMO for COVID ARDS",
      "CPR/ACLS: AHA 2020 guidelines — new compression targets, TTM update (32-36°C)",
      "Neurocritical care: updated TBI protocols, multimodal monitoring",
      "ARDS: Berlin definition, COVID-ARDS nuances, driving pressure concept",
      "Vasopressors: norepinephrine-first evidence (CATS/SOAP-II), vasopressin role",
      "Dexmedetomidine: evidence for ICU sedation and delirium prevention",
      "Liberation: updated ventilator weaning SBT protocols",
    ],
    C.red, C.green
  );
}

// Regional
{
  const s = contentSlide("Regional Anesthesia — Ch 42 (was Ch 46): US-Guided Techniques", C.purple);
  compareBoxes(s,
    "9th Edition Regional\n(Ch 46: Peripheral Nerve Blocks)",
    [
      "Ultrasound guidance: covered but not the central focus",
      "Traditional landmark & nerve stimulator techniques still prominent",
      "LAST: covered in local anesthetic chapter",
      "Fascial plane blocks: mentioned (e.g., TAP block)",
      "FICB, serratus, PECS: limited coverage",
      "No formal LAST checklist referenced",
      "Opioid-sparing role of regional: mentioned",
    ],
    "10th Edition Regional\n(Ch 42: US-Guided Regional + POCUS)",
    [
      "Ultrasound-guided approach: primary methodology throughout",
      "Landmark techniques retained as backup only",
      "LAST: updated ASRA 2020 checklist — lipid emulsion protocols",
      "Erector spinae plane (ESP) block — full new coverage",
      "PECS I & II, serratus, quadratus lumborum (QL) blocks — expanded",
      "Fascial plane blocks for thoracic surgery (ESPB, paravertebral)",
      "Continuous nerve block catheters & ambulatory regional",
      "Opioid-free anesthesia protocols with regional as core",
    ],
    C.red, C.green
  );
}

// ══════════════════════════════════════════════════════════════════════════════
// SECTION 7 — EDITORIAL CHANGES
// ══════════════════════════════════════════════════════════════════════════════
sectionDivider(7, "Editorial & Presentation Changes", "New editor, book design, and readability improvements");

{
  const s = pres.addSlide();
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:"100%", h:"100%", fill:{color:C.ltgray} });
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:"100%", h:1.1, fill:{color:C.darkgray} });
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:0.06, h:"100%", fill:{color:C.gold} });
  s.addText("Editorial Board, Book Design & Usability Changes", { x:0.25, y:0.15, w:13, h:0.75, fontSize:24, bold:true, color:C.white, margin:0 });

  // Editors comparison
  s.addShape(pres.ShapeType.roundRect, { x:0.25, y:1.2, w:6.1, h:2.8, fill:{color:C.white}, rectRadius:0.12, line:{color:C.red, width:1.5} });
  s.addShape(pres.ShapeType.rect, { x:0.25, y:1.2, w:6.1, h:0.45, fill:{color:C.red} });
  s.addText("9th Edition Editors", { x:0.35, y:1.2, w:5.9, h:0.45, fontSize:13, bold:true, color:C.white, align:"center", valign:"middle" });
  s.addText([
    { text: "Lead: ", options:{bold:true} },{ text: "Michael A. Gropper, MD, PhD\n", options:{} },
    { text: "Ronald D. Miller, MD, MS\n", options:{} },
    { text: "Lars I. Eriksson, MD\n", options:{} },
    { text: "Lee A. Fleisher, MD\n", options:{} },
    { text: "Jeanine P. Wiener-Kronish, MD\n", options:{} },
    { text: "Neal H. Cohen, MD, MPH, MS\n", options:{} },
    { text: "Kate Leslie, MD\n", options:{} },
  ], { x:0.4, y:1.75, w:5.8, h:2.1, fontSize:11.5, color:C.darkgray, fontFace:"Calibri" });

  s.addShape(pres.ShapeType.roundRect, { x:6.95, y:1.2, w:6.1, h:2.8, fill:{color:C.white}, rectRadius:0.12, line:{color:C.green, width:1.5} });
  s.addShape(pres.ShapeType.rect, { x:6.95, y:1.2, w:6.1, h:0.45, fill:{color:C.green} });
  s.addText("10th Edition Editors", { x:7.05, y:1.2, w:5.9, h:0.45, fontSize:13, bold:true, color:C.white, align:"center", valign:"middle" });
  s.addText([
    { text: "Lead: ", options:{bold:true} },{ text: "Michael A. Gropper, MD, PhD\n", options:{} },
    { text: "Lars I. Eriksson, MD\n", options:{} },
    { text: "Lee A. Fleisher, MD\n", options:{} },
    { text: "Neal H. Cohen, MD, MPH, MS\n", options:{} },
    { text: "Kate Leslie, MD\n", options:{} },
    { text: "Oluwaseun Johnson-Akeju, MD  ", options:{bold:true} },{ text: "★ NEW\n", options:{color:C.gold, bold:true} },
    { text: "Ronald Miller: retired from active editorial role", options:{color:C.midgray, italic:true} },
  ], { x:7.1, y:1.75, w:5.8, h:2.1, fontSize:11.5, color:C.darkgray, fontFace:"Calibri" });

  // Design changes
  s.addShape(pres.ShapeType.roundRect, { x:0.25, y:4.15, w:12.8, h:3.4, fill:{color:C.white}, rectRadius:0.12, line:{color:C.darkgray, width:1} });
  s.addText("Book Design & Pedagogical Changes", { x:0.4, y:4.25, w:12.5, h:0.4, fontSize:13, bold:true, color:C.darkgray, margin:0 });
  const designItems = [
    ["Chapter structure", "More cohesive logical progression from basic science → clinical application throughout both volumes"],
    ["Key points boxes", "Expanded 'Key Points' summary boxes at chapter start — exam-targeted"],
    ["Online content", "Updated online videos, interactive figures, and clinical cases"],
    ["Reading ease", "Dense 9th ed text restructured with subheadings for easier navigation in 10th ed"],
    ["Evidence grading", "Updated RCT and guideline references — post-2019 literature incorporated throughout"],
    ["Special populations", "Expanded coverage: elderly, obese, pregnant, and LMIC patients given more space"],
  ];
  designItems.forEach(([label, text], i) => {
    const y = 4.7 + i * 0.43;
    s.addText(label + ":", { x:0.4, y, w:2.2, h:0.38, fontSize:11, bold:true, color:C.blue, margin:0 });
    s.addText(text, { x:2.65, y, w:10.2, h:0.38, fontSize:11, color:C.darkgray, fontFace:"Calibri", margin:0 });
  });
}

// ══════════════════════════════════════════════════════════════════════════════
// SECTION 8 — COMPREHENSIVE CHAPTER MAP
// ══════════════════════════════════════════════════════════════════════════════
sectionDivider(8, "Side-by-Side Chapter Map", "Where to find topics — 9th vs 10th edition numbering");

{
  const s = pres.addSlide();
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:"100%", h:"100%", fill:{color:C.ltgray} });
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:"100%", h:1.0, fill:{color:C.navy} });
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:0.06, h:"100%", fill:{color:C.gold} });
  s.addText("Chapter Mapping — Find the Same Topic in Each Edition", { x:0.25, y:0.12, w:13, h:0.72, fontSize:22, bold:true, color:C.white, margin:0 });

  const headers2 = ["Topic", "9th Ed Chapter", "10th Ed Chapter", "Change Summary"];
  const mapRows = [
    ["Immune System & Anesthesia", "—  (Not present)", "Ch 26 ★ NEW", "Entirely new — COVID/immune evidence"],
    ["Emergency Preparedness", "Ch 68 (limited)", "Ch 85 ★ NEW", "Full chapter — pandemic lessons"],
    ["Perioperative Echocardiography + POCUS", "Ch 37", "Ch 33", "POCUS comprehensively added"],
    ["Airway Management", "Ch 44", "Ch 40", "Updated DAS 2015, ASA 2022, HFNO, eFONA"],
    ["Neurocognitive Disorders", "Ch 83", "Ch 78", "Renamed (NCD), new biomarkers, EEG monitoring"],
    ["Perioperative Fluid Therapy", "Ch 47", "Ch 43", "Updated GDFT targets, crystalloid vs colloid"],
    ["Regional Anesthesia (Peripheral)", "Ch 46", "Ch 42", "US-guided primary, ESP/PECS added, LAST update"],
    ["Intravenous Anesthetics", "Ch 23 (IV drugs + TIVA)", "Ch 21", "Remimazolam, updated TCI models"],
    ["Neuromuscular Blockers", "Ch 27", "Ch 24", "Sugammadex updated dosing, TOFR >0.9 target"],
    ["Opioids", "Ch 24", "Ch 22", "OIH, opioid-sparing, opioid-free anesthesia"],
    ["Pediatric Anesthesia", "Ch 77 (single broad chapter)", "Ch 70-72 (expanded)", "Subdivided, neonatal expanded"],
    ["Cardiac Surgery Anesthesia", "Ch 54", "Ch 50", "VA-ECMO, new hemodynamic targets updated"],
    ["Critical Care", "Ch 84", "Ch 79", "ARDS Berlin, COVID protocols, updated vasopressors"],
    ["CPR / ACLS", "Ch 87 — AHA 2015", "Ch 82 — AHA 2020", "Updated compression targets, TTM 32-36°C"],
    ["Occupational Safety", "Ch 92", "Ch 84", "COVID exposure, PPE protocols added"],
    ["Sustainability", "— (not present)", "Throughout + Section 1", "NEW — environmental impact of volatile agents"],
  ];

  const hW = [3.2, 2.1, 2.1, 5.4];
  const hX = [0.2, 3.42, 5.54, 7.66];
  const rH = 0.37;
  const sY = 1.1;

  headers2.forEach((h,ci) => {
    s.addShape(pres.ShapeType.rect, { x:hX[ci], y:sY, w:hW[ci], h:0.4, fill:{color:C.navy} });
    s.addText(h, { x:hX[ci]+0.05, y:sY, w:hW[ci]-0.1, h:0.4, fontSize:11, bold:true, color:C.white, valign:"middle", margin:0 });
  });
  mapRows.forEach((row, ri) => {
    const y = sY + 0.4 + ri * rH;
    const bg = ri % 2 === 0 ? C.white : "EEF4FA";
    row.forEach((cell, ci) => {
      const textColor = ci===1 && cell.includes("Not") ? C.red : (ci===2 && cell.includes("★") ? C.green : C.darkgray);
      s.addShape(pres.ShapeType.rect, { x:hX[ci], y, w:hW[ci], h:rH, fill:{color:bg}, line:{color:"D0D7DE", width:0.3} });
      s.addText(cell, { x:hX[ci]+0.06, y:y+0.02, w:hW[ci]-0.12, h:rH-0.04, fontSize:9.5, color:textColor, bold:cell.includes("★"), valign:"middle", shrinkText:true });
    });
  });
}

// ══════════════════════════════════════════════════════════════════════════════
// SLIDE — WHAT DOES NOT CHANGE
// ══════════════════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:"100%", h:"100%", fill:{color:C.ltgray} });
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:"100%", h:1.1, fill:{color:"4A6741"} });
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:0.06, h:"100%", fill:{color:C.gold} });
  s.addText("What Remains Unchanged — The Core of Miller's", { x:0.25, y:0.15, w:13, h:0.75, fontSize:24, bold:true, color:C.white, margin:0 });

  const constant = [
    ["Physiology sections", "Basic cardiovascular, respiratory, renal, neurologic, and hepatic physiology — still comprehensive, considered the best basic science review in anesthesia"],
    ["Pharmacology foundations", "Volatile anesthetic mechanisms (Meyer-Overton, protein receptor theories), uptake & distribution, MAC concept — foundational content unchanged"],
    ["Monitoring principles", "Cardiovascular monitoring (arterial, CVP, PA catheter), respiratory monitoring, neuromuscular monitoring — principles stable"],
    ["Surgical subspecialties", "Thoracic, vascular, urologic, ENT, robotic, ambulatory anesthesia — updated content but stable organization"],
    ["Pain management", "Chronic pain chapter, acute postoperative pain — core content retained, evidence-updated"],
    ["Obstetric anesthesia", "Neuraxial techniques for labor & C-section, maternal physiology — retained and updated"],
    ["Book format", "Two-volume set continues; designed for both reference and study use"],
    ["Dr. Ronald Miller's legacy", "Founder and spirit of the book — his philosophy of evidence-based, comprehensive, physiology-first anesthesia remains unchanged"],
  ];

  constant.forEach(([label, text], i) => {
    const y = 1.2 + i * 0.74;
    s.addShape(pres.ShapeType.roundRect, { x:0.25, y, w:12.8, h:0.68, fill:{color:C.white}, rectRadius:0.08, line:{color:"BDD5B8", width:0.5} });
    s.addShape(pres.ShapeType.roundRect, { x:0.25, y, w:2.8, h:0.68, fill:{color:"E8F5E9"}, rectRadius:0.08 });
    s.addText(label, { x:0.35, y:y+0.08, w:2.6, h:0.5, fontSize:11.5, bold:true, color:"2E7D32", fontFace:"Calibri", margin:0 });
    s.addText(text, { x:3.18, y:y+0.07, w:9.75, h:0.54, fontSize:10.5, color:C.darkgray, fontFace:"Calibri", margin:0 });
  });
}

// ══════════════════════════════════════════════════════════════════════════════
// FINAL SUMMARY SLIDE
// ══════════════════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:"100%", h:"100%", fill:{color:C.navy} });
  s.addShape(pres.ShapeType.rect, { x:0, y:0, w:0.06, h:"100%", fill:{color:C.gold} });
  s.addShape(pres.ShapeType.rect, { x:0.25, y:1.0, w:12.8, h:0.05, fill:{color:C.gold} });
  s.addText("KEY TAKEAWAYS", { x:0.25, y:0.2, w:13, h:0.65, fontSize:14, bold:true, color:C.gold, charSpacing:8, margin:0 });
  s.addText("What Every Resident Must Know: 9th vs 10th Edition", { x:0.25, y:0.7, w:13, h:0.3, fontSize:11, color:C.midgray, italic:true, margin:0 });

  const takeaways = [
    { num:"1", title:"2 Brand-New Chapters", body:"Immune System (Ch 26) + Emergency Preparedness (Ch 85) — both reflect post-2019 world realities (COVID, cancer immunology, disaster medicine)", color:C.purple },
    { num:"2", title:"POCUS — The Biggest Technology Addition", body:"Ch 33 now combines perioperative echo AND point-of-care ultrasound — lung, vascular access, abdominal, pediatric POCUS all covered", color:C.teal },
    { num:"3", title:"New Editor Brings Global Perspective", body:"Dr. Johnson-Akeju adds global health equity emphasis — 5 billion people lack surgical access; anesthesia as public health is a new lens", color:C.blue },
    { num:"4", title:"COVID-19 Woven Throughout", body:"Airway modifications, immune chapter, ICU protocols, OR safety — the pandemic changed anesthesia and the 10th edition reflects this fully", color:C.orange },
    { num:"5", title:"Sustainability — A New Ethical Dimension", body:"Desflurane's GWP 2540× CO₂ — many centres have removed it. Green anesthesia content is entirely new to the 10th edition", color:C.green },
    { num:"6", title:"Updated Pharmacology", body:"Remimazolam, updated sugammadex dosing, opioid-free anesthesia framework, updated TCI models — stay current with 10th ed for drug questions", color:C.gold },
    { num:"7", title:"Perioperative Neurocognitive Disorders — Renamed & Expanded", body:"POCD replaced by PACD/POCD/PODS consensus terminology. New biomarkers (NfL, GFAP) and BIS-guided prevention protocols added", color:C.red },
  ];

  takeaways.forEach((t, i) => {
    const row = Math.floor(i / 4);
    const col = i % 4;
    const x = 0.25 + col * 3.26;
    const y = 1.2 + row * 2.85;
    const w = 3.15;
    const h = 2.6;
    s.addShape(pres.ShapeType.roundRect, { x, y, w, h, fill:{color:"0D1F35"}, rectRadius:0.15, line:{color:t.color, width:1.5} });
    s.addShape(pres.ShapeType.roundRect, { x:x+0.1, y:y+0.1, w:0.5, h:0.5, fill:{color:t.color}, rectRadius:0.08 });
    s.addText(t.num, { x:x+0.1, y:y+0.1, w:0.5, h:0.5, fontSize:18, bold:true, color:C.white, align:"center", valign:"middle" });
    s.addText(t.title, { x:x+0.7, y:y+0.1, w:w-0.85, h:0.55, fontSize:11, bold:true, color:t.color, fontFace:"Calibri", margin:0 });
    s.addText(t.body, { x:x+0.15, y:y+0.75, w:w-0.3, h:1.7, fontSize:9.5, color:C.white, fontFace:"Calibri" });
  });

  s.addText("Miller's Anesthesia 10th Edition (2024) — Reviewed for BJA Sept 2025: 'Gold standard reference for anaesthesia in North America'", {
    x:0.25, y:7.15, w:13, h:0.28, fontSize:9, color:C.midgray, italic:true, align:"center",
  });
}

// ══════════════════════════════════════════════════════════════════════════════
pres.writeFile({ fileName: "/home/daytona/workspace/millers-pptx/Millers_10th_vs_9th_Edition.pptx" })
  .then(() => console.log("✅ Presentation saved successfully"))
  .catch(err => console.error("❌ Error:", err));

Running Command

cd /home/daytona/workspace/millers-pptx && node build.js 2>&1

Running Command

ls -lh /home/daytona/workspace/millers-pptx/Millers_10th_vs_9th_Edition.pptx

Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.

differences between the 10th edition millers anaesthesia textbook to 9th ed millers - and explain to me the changes with reasons

Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.

This is a shared conversation. Sign in to Orris to start your own chat.